Job Code 294MM
Fate’s Cancer Immunotherapy group is seeking a motivated individual with expertise in cancer biology, immunology, cell biology or related field to join a multidisciplinary team dedicated to the discovery of novel off-the-shelf cellular therapeutics for the treatment of cancer and other disorders. The successful candidate will be responsible for the development and optimization of novel engineered lymphoid differentiation protocols, including the derivation of off-the-shelf CAR-T cells, from induced pluripotent stem cells (iPSC) as well as their functional assessment in various tumor models. The candidate will play a key role in research activities related to Memorial Sloan Kettering Cancer Center collaboration. The candidate must have experience with mammalian cell culture. The candidate will also play a key role in collaborating with top academic institutes to support discovery, manufacturing and clinical trials. This is a full-time position reporting to a Senior Scientist in Cancer Immunotherapy leading several off-the-shelf CART Product Development programs and is located at our New York Site in New York City, New York.
Download a PDF of the job description for more details:
For consideration send cover letter and curriculum vitae to: email@example.com and reference job 294MM.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.